PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/00 — A2

(11) International Publication Number: WO 00/44361

(43) International Publication Date: 3 August 2000 (03.08.00)

(21) International Application Number: PCT/GB00/00164

(22) International Filing Date: 21 January 2000 (21.01.00)

(30) Priority Data:
9901809.5 27 January 1999 (27.01.99) GB

(71) Applicant *(for all designated States except US)*: LAXDALE LIMITED [GB/GB]; Kings Park House, Laurelhill Business Park, Stirling FK7 9JQ (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: PEET, Malcolm [GB/GB]; 15 Westbourne Avenue, Sheffield S10 2QQ (GB). VADDADI, Krishnarao, Sitamrao [AU/AU]; 53 Websters Road, Temple Stowe, Melbourne, 3106 (AU).

(74) Agent: WAKERLEY, Helen, Rachael; Reddie & Grose, 16 Theobalds Road, London WC1X 9PL (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES FOR PSYCHIATRIC AND NEUROLOGICAL DISORDERS

(57) Abstract

A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90 %, and preferably at least 95 %, is in the form of EPA and where less than 5 %, and preferably less than 3 %, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.